Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 8:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,155 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single Ascending Dose of Placebo Clear all

Conditions: Healthy
Interventions: IW-1973, Matching Placebo Tablet; Drug
Lead sponsor: Cyclerion Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions: PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant, Placebo subcutaneous healthy participant, PF-06755347 subcutaneous ITP; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: CB03-154, Placebo; Drug
Lead sponsor: Shanghai Zhimeng Biopharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Healthy Volunteers
Interventions: AZD1656; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 40 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Glendale, California

Conditions: Type 2 Diabetes
Interventions: MEDI-4166, Placebo; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 11
States / cities: Anniston, Alabama • Chula Vista, California • Jacksonville, Florida + 7 more

Conditions: Rheumatoid Arthritis
Interventions: SKI-O-703 capsule, Placebo capsule; Drug
Lead sponsor: Oscotec Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: LY3819469, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Cypress, California • Miami, Florida • San Antonio, Texas

Conditions: Asthma
Interventions: VAK694, VAK694 placebo, QAX576, QAX576 placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Healthy Adult Participants
Interventions: GSM-779690T, Placebo; Drug · Other
Lead sponsor: Acta Pharmaceuticals; Industry
Eligibility: 20 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: Efinopegdutide, Placebo, Acetaminophen; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Multiple Sclerosis
Interventions: VX15/2503, Placebo; Drug
Lead sponsor: Vaccinex Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 10
States / cities: Cullman, Alabama • Aurora, Colorado • Indianapolis, Indiana + 7 more

Conditions: Systemic Lupus Erythematosus
Interventions: CUG252, Placebo; Drug
Lead sponsor: Cugene Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Bipolar Depression
Interventions: PF-04455242, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Schizophrenia
Interventions: SEP-363856, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Glendale, California • Long Beach, California

Conditions: Healthy
Interventions: LY4005130, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Volunteers
Interventions: (Part A) MKND-201, Placebo, (Part B) MKND-201; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Adult Volunteers
Interventions: BMS-986090, Placebo matching with BMS-986090, Keyhole limpet hemocyanin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Malaria, Healthy Participants
Interventions: E1018, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Participants, Chronic Spontaneous Urticaria
Interventions: AK006-IV, Placebo-IV, AK006-SC, Placebo-SC; Drug
Lead sponsor: Allakos Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 19
States / cities: Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 16 more

Conditions: Systemic Lupus Erythematosus
Interventions: AMG 570, AMG 570 Matching Placebo; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Evansville, Indiana • Overland Park, Kansas • Madison, Wisconsin

Conditions: HIV Infections
Interventions: VH4770359, Placebo, Midazolam; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Renal Insufficiency, Chronic, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
Interventions: Intravenous Gemini, Intravenous placebo; Drug
Lead sponsor: Revelation Biosciences, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 3
States / cities: Chula Vista, California • La Mesa, California • San Antonio, Texas

Conditions: Rheumatoid Arthritis
Interventions: FB704A, Placebo; Drug
Lead sponsor: Fountain Biopharma Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Atopy
Interventions: AK001, Placebo; Drug
Lead sponsor: Allakos Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cypress, California

Search by objective public record fields.

Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants

A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers

A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes

Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers

A Study of LY3819469 in Healthy Participants

To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma

A Clinical Trial to Study Single- and Multiple- Doses of GSM-779690T in Healthy Participants

A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)

Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS

A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers

A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers

A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

A Study of LY4005130 in Healthy Participants

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers

Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects

A Study of Oral E1018 in Healthy Adult Participants

Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria

Single Ascending Dose Study of AMG 570 in Healthy Subjects

A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.

Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001